China trials new HIV vaccine on humans

China which has 840,000 people with HIV, a conservative estimate say experts, will carry out the very first trials of a new virus on human guinea pigs.

The Chinese government says 80,000 of its 1.3 billion population have developed full-blown AIDS. Fortynine volunteers aged between 18 and 50 will take part in the tests which will be carried out over three stages.

A 20-year-old man became the first volunteer to receive the vaccine a few days ago and seven others, four of whom are women will shortly follow suit.

Chen Ji, director of the disease control agency in southern China's Guangxi region, says the first stage of the test will last 14 months, very little detail of the test has been given, but the second stage is expected to cover "immune nature and safety of the vaccine". All taking part in the tests have had physical check-ups and signed waivers.

The tests were approved by China's drug regulators last November. The UN has warned that the number of people affected by HIV and Aids in China could rise to 10 million by 2010 unless much more is done to fight the disease. Over 43 million people around the world have been infected by the HIV/Aids virus and around 25 million people have died.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Community partnerships lead to more inclusive health care for neurodiverse individuals